Valdez Hernan, Mitsuyasu Ronald, Landay Alan, Sevin Anne D, Chan Ellen S, Spritzler John, Kalams Spyros A, Pollard Richard B, Fahey John, Fox Lawrence, Namkung Ann, Estep Scharla, Moss Ronald, Sahner David, Lederman Michael M
Case Western Reserve University and University Hospitals of Cleveland, Ohio 44106, USA.
J Infect Dis. 2003 Jan 15;187(2):320-5. doi: 10.1086/346056. Epub 2003 Jan 6.
To ascertain whether CD4(+) lymphocyte increases induced by interleukin (IL)-2 enhanced in vivo immune responses, 38 human immunodeficiency virus (HIV)-infected patients who had received highly active antiretroviral therapy (HAART) or HAART and IL-2 for at least 60 weeks were immunized with tetanus toxoid, inactivated glycoprotein 120-depleted HIV-1, and hepatitis A and B vaccines. Despite dramatic increases in CD4(+) lymphocyte counts, IL-2 did not enhance immunization responses.
为确定白细胞介素（IL）-2诱导的CD4(+)淋巴细胞增加是否能增强体内免疫反应，对38例接受高效抗逆转录病毒治疗（HAART）或HAART联合IL-2至少60周的人类免疫缺陷病毒（HIV）感染患者接种破伤风类毒素、灭活的去除糖蛋白120的HIV-1以及甲型和乙型肝炎疫苗。尽管CD4(+)淋巴细胞计数显著增加，但IL-2并未增强免疫反应。
Zotero 插件